{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:59:03Z","timestamp":1790272743649,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["(CAPES) - Finance Code 001"],"award-info":[{"award-number":["(CAPES) - Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"DOI":"10.3389\/fmolb.2020.00170","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T04:17:41Z","timestamp":1597897061000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evidence for Disruption of Mg2+ Pair as a Resistance Mechanism Against HIV-1 Integrase Strand Transfer Inhibitors"],"prefix":"10.3389","volume":"7","author":[{"given":"Lucas de Almeida","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Ramos","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3851\/imp2878","article-title":"Short communication Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.","volume":"20","author":"Akil","year":"2015","journal-title":"Antivir. Ther."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy.","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/s0006-3495(03)74958-3","article-title":"Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistance.","volume":"84","author":"Barreca","year":"2003","journal-title":"Biophys. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath.","volume":"81","author":"Berendsen","year":"1984","journal-title":"J. Chem. Phys."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications.","volume":"203","author":"Blanco","year":"2011","journal-title":"J. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling.","volume":"126","author":"Bussi","year":"2007","journal-title":"J. Chem. Phys."},{"key":"B7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/qai.0000000000002275","article-title":"Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment\u2013Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.","volume":"83","author":"Cahn","year":"","journal-title":"JAIDS"},{"key":"B8","article-title":"Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-Week results from the GEMINI studies","author":"Cahn","year":"","journal-title":"Proceedings of the 10th IAS Conference on HIV Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1468-1293.2008.00628.x","article-title":"Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.","volume":"9","author":"Charpentier","year":"2008","journal-title":"HIV Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.aay4919","article-title":"Structural basis of second-generation HIV integrase inhibitor action and viral resistance.","volume":"367","author":"Cook","year":"2020","journal-title":"Science"},{"key":"B11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.","volume":"359","author":"Cooper","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"23213","DOI":"10.1074\/jbc.r100027200","article-title":"HIV integrase, a brief overview from chemistry to therapeutics.","volume":"276","author":"Craigie","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u22c5 log (N) method for Ewald sums in large systems.","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077448","article-title":"Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.","volume":"8","author":"DeAnda","year":"2013","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23599","DOI":"10.1074\/jbc.m804213200","article-title":"Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.","volume":"283","author":"Dicker","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method.","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"B17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2007.43.12.1146063","article-title":"Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.","volume":"43","author":"Evering","year":"2007","journal-title":"Drugs Today"},{"key":"B18","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1073\/pnas.90.6.2399","article-title":"Inhibitors of human immunodeficiency virus integrase.","volume":"90","author":"Fesen","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0076-6879(03)74020-8","article-title":"Modeller: generation and refinement of homology-based protein structure models.","volume":"374","author":"Fiser","year":"2003","journal-title":"Methods Enzymol."},{"key":"B20","article-title":"Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways.","volume":"13","author":"Fransen","year":"2008","journal-title":"Antiviral Ther."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0b013e3181c9c967","article-title":"Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.","volume":"53","author":"Gatell","year":"2010","journal-title":"J. Acquired Immune Deficiency Syndr."},{"key":"B22","article-title":"Mechanism by which the HIV integrase active-site mutation N155H confers resistance to raltegravir.","author":"Grobler","year":"2008","journal-title":"Antiviral Ther."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature08784","article-title":"Retroviral intasome assembly and inhibition of DNA strand transfer.","volume":"464","author":"Hare","year":"","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.","volume":"107","author":"Hare","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012.","volume":"58","author":"Hurt","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1128\/mcb.12.5.2331","article-title":"Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral\/retrotransposon integrases and bacterial insertion sequence transposases.","volume":"12","author":"Kulkosky","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymeth.2009.02.001","article-title":"Nucleoprotein complex intermediates in HIV-1 integration.","volume":"47","author":"Li","year":"2009","journal-title":"Methods"},{"key":"B28","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side-chain torsion potentials for the Amber ff99SB protein force field.","volume":"78","author":"Lindorff-Larsen","year":"2010","journal-title":"Proteins"},{"key":"B29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/jac\/dkp014","article-title":"Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.","volume":"63","author":"Malet","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1021\/bi800791q","article-title":"Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.","volume":"47","author":"Marinello","year":"2008","journal-title":"Biochemistry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.antiviral.2009.11.004","article-title":"Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.","volume":"85","author":"McColl","year":"2010","journal-title":"Antiviral Res."},{"key":"B32","article-title":"Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005 a Phase II study in treatment-experienced patients.","author":"Miller","year":"2008","journal-title":"Antivir. Ther."},{"key":"B33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: consistent treatment of internal and surface residues in empirical p K a predictions.","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theor. Comput."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: a new molecular dynamics method.","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."},{"key":"B35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1126\/science.aay8015","article-title":"Structural basis for strand-transfer inhibitor binding to HIV intasomes.","volume":"367","author":"Passos","year":"2020","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.aah5163","article-title":"Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome.","volume":"355","author":"Passos","year":"2017","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1517\/13543776.2011.586631","article-title":"New first and second generation inhibitors of human immunodeficiency virus-1 integrase.","volume":"21","author":"Pendri","year":"2011","journal-title":"Exp. Opin. Ther. Patents"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-6-25","article-title":"Raltegravir, elvitegravir, and metoogravir: the birth of\u201cme-too\u201d HIV-1 integrase inhibitors.","volume":"6","author":"Serrao","year":"2009","journal-title":"Retrovirology"},{"key":"B39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.01534-07","article-title":"Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137).","volume":"82","author":"Shimura","year":"2008","journal-title":"J. Virol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3851\/imp1397","article-title":"Elvitegravir: a new HIV integrase inhibitor.","volume":"20","author":"Shimura","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"B41","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile.","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free.","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1021\/ct800162v","article-title":"Study of the conformational dynamics of the catalytic loop of WT and G140A\/G149A HIV-1 integrase core domain using reversible digitally filtered molecular dynamics.","volume":"5","author":"Williams","year":"2009","journal-title":"J. Chem. Theory Comput."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmolb.2020.00170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T23:38:37Z","timestamp":1667950717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmolb.2020.00170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":43,"alternative-id":["10.3389\/fmolb.2020.00170"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2020.00170","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"article-number":"170"}}